Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis

• Maria C. Lebre ,

  Contributed equally to this work with: Maria C. Lebre, Clarissa E. Vergunst

  * E-mail: c.lebre@amc.uva.nl

  Affiliation Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

  ⨯
• Clarissa E. Vergunst ,

  Contributed equally to this work with: Maria C. Lebre, Clarissa E. Vergunst

  Affiliation Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

  ⨯
• Ivy Y. K. Choi,

  Affiliation Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

  ⨯
• Saïda Aarrass,

  Affiliation Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

  ⨯
• Ana S. F. Oliveira,

  Affiliation Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

  ⨯
• Tim Wyant,

  Affiliation Millennium Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Richard Horuk,

  Affiliation Department of Pharmacology, University of California Davis, Davis, California, United States of America

  ⨯
• Kris A. Reedquist,

  Affiliation Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

  ⨯
• Paul P. Tak

  Affiliation Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

  ⨯